Bethea Brian T, Fitton Torin P, Alejo Diane E, Barreiro Christopher J, Cattaneo Stephen M, Dietz Harry C, Spevak Philip J, Lima Joao A C, Gott Vincent L, Cameron Duke E
Division of Cardiac Surgery, Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Ann Thorac Surg. 2004 Sep;78(3):767-72; discussion 767-72. doi: 10.1016/j.athoracsur.2004.03.040.
Valve-sparing operations for aortic root aneurysms are increasing in frequency, but techniques and results are still in evolution. We reviewed our experience with 65 patients (adults and children) who had this operation at our institution to determine early and late outcomes.
A retrospective clinical review was undertaken using hospital records, clinical and echocardiographic, computed tomography, magnetic resonance imaging data, and telephone interviews with patients and their physicians.
Between July 1994 and December 2002, 65 patients (46 adults and 19 children) underwent a valve-sparing operation for aortic root aneurysm. Forty-four of the patients had the Marfan syndrome; the remaining 21 had either a nonspecific connective tissue disorder (14 patients) or a miscellaneous disease process such as Ehlers-Danlos syndrome (7 patients). Fifty-eight (89%) had a David II (remodeling) procedure and 7 had a David I (reimplantation) procedure. The DePaulis "Valsalva graft" was used in six of the David I patients. There were no operative or hospital deaths; only one late death occurred in an adult due to salmonella meningitis. Overall, survival was 100% at one year and 98% at 3 and 5 years. Ten patients (7 adults and 3 children) developed significant late aortic insufficiency (AI). Nine of these patients had a David II procedure and in 8 of these cases, AI was secondary to significant late annular dilatation. One of the 10 patients developed late AI 8.2 years after a David I procedure; his AI was secondary to aortic leaflet extension and prolapse. Six of the 10 patients who developed significant late AI required aortic valve replacement (4 adults and 2 children). Freedom from late aortic valve replacement (AVR) in this series of 65 patients was 91% at 3 and 84% at 5 years. At the close of this study, 58 patients were New York Heart Association (NYHA) class I and 6 were NYHA class II; no patients were class III or IV. There were no episodes of endocarditis or clinically significant thromboembolism.
Valve-sparing operations provide satisfactory results for many patients with an aortic root aneurysm, but the David II remodeling procedure has a greater risk of late annular dilatation and AI. The David I reimplantation procedure utilizing the DePaulis Valsalva graft may obviate this problem.
保留瓣膜的主动脉根部动脉瘤手术的实施频率在不断增加,但技术和结果仍在发展中。我们回顾了在我院接受该手术的65例患者(成人和儿童)的经验,以确定早期和晚期结果。
采用医院记录、临床及超声心动图、计算机断层扫描、磁共振成像数据,以及对患者及其医生的电话访谈进行回顾性临床研究。
1994年7月至2002年12月期间,65例患者(46例成人和19例儿童)接受了保留瓣膜的主动脉根部动脉瘤手术。44例患者患有马方综合征;其余21例患有非特异性结缔组织疾病(14例患者)或诸如埃勒斯-当洛综合征等其他疾病过程(7例患者)。58例(89%)接受了大卫II型(重塑)手术,7例接受了大卫I型(重新植入)手术。6例大卫I型患者使用了德保利斯“主动脉窦移植物”。无手术或院内死亡;仅1例成人因沙门氏菌脑膜炎发生晚期死亡。总体而言,1年生存率为100%,3年和5年生存率为98%。10例患者(7例成人和3例儿童)出现严重的晚期主动脉瓣关闭不全(AI)。其中9例患者接受了大卫II型手术,8例患者的AI继发于严重的晚期瓣环扩张。10例患者中有1例在大卫I型手术后8.2年出现晚期AI;其AI继发于主动脉瓣叶延长和脱垂。10例出现严重晚期AI的患者中有6例需要进行主动脉瓣置换(4例成人和2例儿童)。在这65例患者系列中,3年免于晚期主动脉瓣置换(AVR)的比例为91%,5年为84%。在本研究结束时,58例患者为纽约心脏协会(NYHA)I级,6例为NYHA II级;无III级或IV级患者。无感染性心内膜炎或临床显著血栓栓塞事件。
保留瓣膜手术为许多主动脉根部动脉瘤患者提供了满意的结果,但大卫II型重塑手术有更大的晚期瓣环扩张和AI风险。采用德保利斯主动脉窦移植物的大卫I型重新植入手术可能避免此问题。